



Joe Lombardo  
Governor

# NEVADA HEALTH AUTHORITY

**Nevada Medicaid**  
4070 Silver Sage Drive  
Carson City, NV 89701  
[NVHA.NV.GOV](http://NVHA.NV.GOV)



Stacie Weeks, Director  
Ann Jensen, Administrator

## Silver State Scripts Board Meeting Minutes

**Date of Meeting:** Thursday, December 11, 2025, at 1:00 PM

**Name of Organization:** The State of Nevada, Nevada Health Authority, Nevada Medicaid, Silver State Scripts Board.

Agenda Item	Record	Notes																					
<b>1. Closed Executive Session</b>																							
<b>a. Call to Order and Roll Call</b>	<p>Chairperson Mark Decerbo called the meeting to order at 1:05 PM on December 11, 2025.</p> <p>Chairperson Decerbo took the roll.</p> <table> <tr> <th></th><th>Present</th><th>Absent</th></tr> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Mark Crumby, Pharm. D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Staci Dooley, APRN-C.</td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr> </table>		Present	Absent	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm. D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Staci Dooley, APRN-C.	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<p><b>Nevada Medicaid Staff Present were as follows:</b></p> <ul style="list-style-type: none"> <li>• Duncan, Keiko, Pharm.D., Medicaid Pharmacy Director</li> <li>• Brown, Antonio, Chief of Pharmacy</li> <li>• Palomino, Bonnie, Pharmacy Services Manager</li> <li>• Flowers, Ellen, Social Services Program Specialist II</li> <li>• Cabrera, Donna, Program Officer I</li> <li>• Gonzalez, Taylor Rae, Social Services Program Specialist II</li> <li>• Lithier, Gabriel, Deputy Attorney General (DAG)</li> </ul> <p><b>Prime Staff Present were as follows:</b></p>
	Present	Absent																					
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																					
• Mark Crumby, Pharm. D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																					
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																					
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																					
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																					
• Staci Dooley, APRN-C.	<input type="checkbox"/>	<input checked="" type="checkbox"/>																					

		<ul style="list-style-type: none"> <li>• Deoliveira, Brittany, Pharm.D., Clinical Account Manager</li> <li>• Czechowski, Jessica, Pharm.D., Director, Clinical Account Services</li> <li>• Mishra, Raj, Pharm.D., Clinical Account Manager</li> <li>• Martinez, Chris, Sr. Business Analyst</li> <li>• Rivas, Melissa, Sr. Business Analyst</li> </ul>
<b>b. Financial Review of Drug Classes with Proposed Changes</b>	<p>Chairperson Decerbo directed Dr. Brittany Deoliveira to proceed with the financial review of drug classes with proposed changes up for review.</p> <p>Dr. Deoliveira reminded the board members that the financial material presented is confidential and should not be discussed or disclosed outside this closed session of the Silver State Scripts Board meeting.</p> <p>Dr. Deoliveira presented the financial review of the established drug classes with proposed changes, noting the products with proposed changes in PDL status.</p> <ul style="list-style-type: none"> <li>• Androgens</li> <li>• Miscellaneous Heart Failure Agents</li> <li>• Anticoagulants: Oral</li> <li>• Pregnancy-Induced Nausea and Vomiting Treatment</li> <li>• Serotonin-receptor Antagonist/Combo</li> <li>• Anticholinergics and Combination Products</li> <li>• Anti-Hypoglycemic Agents</li> <li>• ADHD Agents</li> </ul> <p>Dr. Deoliveira presented the financial review of the established drug classes being reviewed due to the release of new drugs.</p>	

	<ul style="list-style-type: none"> <li>• Antidepressants, Other</li> <li>• Dipeptidyl Peptidase-4 Inhibitors and Combinations with Metformin</li> <li>• Opiate Antagonists</li> <li>• Multiple Sclerosis Agents: Injectable</li> </ul> <p>Dr. Deoliveira presented the financial review of the new drug classes being reviewed for proposed addition:</p> <ul style="list-style-type: none"> <li>• Neurokinin-1 (NK1) Receptor Antagonists</li> </ul>																						
<b>2. Open Public Meeting</b>																							
<b>a. Call to Order and Roll Call</b>	<p>Chairperson Mark Decerbo called the meeting to order at 2:01 PM on December 11, 2025.</p> <p>A quorum was present.</p> <p>Chairperson Decerbo took the roll.</p> <table> <thead> <tr> <th></th><th>Present</th><th>Absent</th></tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Mark Crumby, Pharm. D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Leana Ramirez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Staci Dooley, APRN-C.</td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr> </tbody> </table>		Present	Absent	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm. D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Staci Dooley, APRN-C.	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<p><b>DHCFP Staff Present were as follows:</b></p> <ul style="list-style-type: none"> <li>• Duncan, Keiko, Pharm.D., Medicaid Pharmacy Director</li> <li>• Brown, Antonio, Chief of Pharmacy &amp;</li> <li>• Palomino, Bonnie, Pharmacy Services Manager</li> <li>• Flowers, Ellen, Social Services Program Specialist II</li> <li>• Cabrera, Donna, Program Officer I</li> <li>• Gonzalez, Taylor Rae, Social Services Program Specialist II</li> <li>• Lithier, Gabriel, Deputy Attorney General (DAG)</li> </ul> <p><b>Prime Staff Present were as follows:</b></p> <ul style="list-style-type: none"> <li>• Deoliveira, Brittany, Pharm.D., Clinical Account Manager</li> </ul>
	Present	Absent																					
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																					
• Mark Crumby, Pharm. D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																					
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																					
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																					
• Leana Ramirez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																					
• Staci Dooley, APRN-C.	<input type="checkbox"/>	<input checked="" type="checkbox"/>																					

		<ul style="list-style-type: none"><li>Czechowski, Jessica, Pharm.D., Director, Clinical Account Services</li><li>Mishra, Raj, Pharm.D., Clinical Account Manager</li><li>Martinez, Chris, Sr. Business Analyst</li><li>Rivas, Melissa, Sr. Business Analyst</li></ul> <p><b>The public attendee list is included as Attachment A.</b></p> <p>Note: Participants may not have chosen to reveal their identity, and in the absence of a sign-in sheet, the attendee list’s accuracy is not assured.</p>																												
<p><b>b. Approval for previous Meeting Minutes from September 18, 2025.</b></p>	<p>Board Member Sapandeep Khurana moved to approve the meeting minutes and Board Member Elizabeth Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Staci Dooley, APRN-C</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Staci Dooley, APRN-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																											
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Mark Crumby, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Leana Ramirez, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Staci Dooley, APRN-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											
<p><b>c. Public Comments</b></p>	<p>Telephonic and web comments were called for, and the phone lines were opened.</p>																													

	No Public comment was provided.	
<b>d. Status Update by DHCFP</b>	<p>Medicaid Pharmacy Director Dr. Keiko Duncan provided an announcement.</p> <ul style="list-style-type: none"> <li>I want to welcome everybody to the last Silver State Scripts meeting of 2025. I feel like I just welcomed everybody to the first one. Well, I'm sure I will be welcoming 2026, coming soon. I just want to thank all the board members and all of the public that attends for all of their hard work that we do in creating this drug list for Nevada Medicaid. Just a reminder for everybody, I know we've mentioned this in past meetings, but our Single Preferred Drug List is going live January 1st, 2026 so there are quite a few web announcements coming out from the state as well as each of our Managed Care Organizations. So I definitely want to refer everybody to those, as that will be going live and I'm sure our first meeting of the New Year will also be discussing that a little bit more.</li> </ul> <p>Chief of Pharmacy Services, Antonio Brown, provided an announcement.</p> <ul style="list-style-type: none"> <li>Thank you everybody for being here. I just have a couple of announcements pertaining to the board. So first we're just sad to announce the departure of two esteemed Board Members, Dr. Adashek and Dr. Singh. Both have been instrumental in the shaping of the board since its creation in 2019, offering invaluable insights as practicing physicians and contributing meaningfully to our mission. Their presence and experience will greatly be missed and we extend our heartfelt thanks and best wishes to them in their future</li> </ul>	

	<p>endeavors. Now it's more exciting news.</p> <p>We are thrilled to welcome a new member to the board, Mrs. Stacy Dooley. Mrs. Dooley is an advanced practice-registered nurse with 16 years of clinical experience in family medicine with strong focus in preventative care and chronic disease management in one's health. We are very, very excited about the knowledge and perspective that she will bring to the board, and we look forward to the contributions that she'll make. So, we can't wait for everybody to meet her.</p> <p>And lastly, just a friendly reminder, we are actively recruiting practicing pharmacists and physicians to join the board.</p> <p>So if you know someone that may be interested, please don't hesitate to reach out to us. And so, with that, thank you so much for all your continued support and dedication.</p>	
<b>3. Clinical Presentations</b>		
<b>A. For Possible Action: Discussion and possible adoption of Androgens.</b>		
i. <u>Public comment</u>	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>	
ii. Drug class review presentation by Prime.	Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.	
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Khurana moved to accept the class as clinically and therapeutically equivalent as presented by Prime, and Board Member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p>	

		<div> <div>Yes</div> <div>No</div> <div>Abst.</div> </div> <ul style="list-style-type: none"> <li>• Mark Decerbo, Pharm.D., Chair <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Mark Crumby, Pharm.D <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Elizabeth Gonzalez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Sapandeep Khurana, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Leana Ramirez, Pharm.D <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Staci Dooley, APRN-C <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/></li> </ul>	
iv.	Presentation of recommendations for PDL inclusion by Prime.	<p>Dr. Deoliveira recommended:</p> <ul style="list-style-type: none"> <li>• Remove Androderm from Preferred Drug List due to product discontinuation</li> <li>• Remove AndroGel gel pump from preferred drug list to avoid confusion, as no NDCs are currently available</li> <li>• Remove AndroGel packet, Fortesta, and testosterone solution from the NPD list due to product discontinuation</li> <li>• Place testosterone gel packet (generic for Vogelxo) as a preferred option, keeping the alternative testosterone gel packet (generic for AndroGel) as non-preferred</li> <li>• And clarify on the NPD side that the testosterone gel (generics for Vogelxo, Axiron, and Fortesta) are non-preferred products</li> </ul>	
v.	Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Gonzalez moved to approve the proposed changes as presented by Prime and Board Member Khurana seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <div> <div>Yes</div> <div>No</div> <div>Abst.</div> </div> <ul style="list-style-type: none"> <li>• Mark Decerbo, Pharm.D., Chair <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Mark Crumby, Pharm.D <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Elizabeth Gonzalez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Sapandeep Khurana, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Leana Ramirez, Pharm.D <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> </ul>	

	<ul style="list-style-type: none"><li>Staci Dooley, APRN-C</li></ul> <div><input type="checkbox"/><input type="checkbox"/><input checked="" type="checkbox"/></div>																													
<b>B. For Possible Action: Discussion and possible adoption of <b>Miscellaneous Heart Failure Agents.</b></b>																														
i. <u>Public comment</u>	Telephonic and web comments were called for, and the phone lines were opened.  No public comment was provided.																													
ii. Drug class review presentation by Prime.	Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.																													
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Khurana moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Board Member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td><ul style="list-style-type: none"><li>Mark Decerbo, Pharm.D., Chair</li></ul></td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td><ul style="list-style-type: none"><li>Mark Crumby, Pharm.D</li></ul></td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td><ul style="list-style-type: none"><li>Elizabeth Gonzalez, Pharm.D.</li></ul></td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td><ul style="list-style-type: none"><li>Sapandeep Khurana, MD</li></ul></td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td><ul style="list-style-type: none"><li>Leana Ramirez, Pharm.D</li></ul></td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td><ul style="list-style-type: none"><li>Staci Dooley, APRN-C</li></ul></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	<ul style="list-style-type: none"><li>Mark Decerbo, Pharm.D., Chair</li></ul>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<ul style="list-style-type: none"><li>Mark Crumby, Pharm.D</li></ul>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<ul style="list-style-type: none"><li>Elizabeth Gonzalez, Pharm.D.</li></ul>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<ul style="list-style-type: none"><li>Sapandeep Khurana, MD</li></ul>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<ul style="list-style-type: none"><li>Leana Ramirez, Pharm.D</li></ul>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<ul style="list-style-type: none"><li>Staci Dooley, APRN-C</li></ul>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																											
<ul style="list-style-type: none"><li>Mark Decerbo, Pharm.D., Chair</li></ul>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
<ul style="list-style-type: none"><li>Mark Crumby, Pharm.D</li></ul>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
<ul style="list-style-type: none"><li>Elizabeth Gonzalez, Pharm.D.</li></ul>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
<ul style="list-style-type: none"><li>Sapandeep Khurana, MD</li></ul>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
<ul style="list-style-type: none"><li>Leana Ramirez, Pharm.D</li></ul>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
<ul style="list-style-type: none"><li>Staci Dooley, APRN-C</li></ul>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											
iv. Presentation of recommendations for PDL inclusion by Prime.	Dr. Deoliveira recommended: <ul style="list-style-type: none"><li>To place sacubitril/valsartan (generic for Entresto) as preferred, and</li></ul>																													



	move the brand Entresto tab from preferred to non-preferred																													
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board member Gonzalez moved to approve the proposed changes as presented by Prime and Chairperson Decerbo seconded the motion.</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Staci Dooley, APRN-C</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Staci Dooley, APRN-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																											
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Mark Crumby, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Leana Ramirez, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Staci Dooley, APRN-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											
C. For Possible Action: Discussion and possible adoption of Anticoagulants: Oral.																														
i. <u>Public Comment</u>	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>																													
ii. Drug class review presentation by Prime.	Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.																													
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Khurana moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Board Member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																					
	Yes	No	Abst.																											
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											

	<ul style="list-style-type: none"><li>• Mark Crumby, Pharm.D</li><li>• Elizabeth Gonzalez, Pharm.D.</li><li>• Sapandeep Khurana, MD</li><li>• Leana Ramirez, Pharm.D</li><li>• Staci Dooley, APRN-C</li></ul>	<div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div> <div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div> <div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div> <div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div> <div><div><input type="checkbox"/></div><div><input type="checkbox"/></div><div><input checked="" type="checkbox"/></div></div>	
iv. Presentation of recommendations for PDL inclusion by Prime.	<p>Dr. Deoliveira recommended:</p> <ul style="list-style-type: none"><li>• Keep Eliquis tablet as preferred, clarify that the Eliquis dose pack is also preferred, and place the Eliquis sprinkle cap and suspension as non-preferred products</li><li>• Keep Xarelto tablet as preferred, clarify that the Xarelto dose pack is also preferred, and move the Xarelto suspension from preferred to non-preferred</li><li>• And lastly, place rivaroxaban (the generic for Xarelto) tablet and suspension as non-preferred</li></ul>		
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Khurana moved to approve the proposed changes as presented by Prime and Board Member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div></div></div></div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div></div><div><div><div><div></div><div></div><div></div>&lt;/</div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div>		

<b>Pregnancy-Induced Nausea and Vomiting Treatment.</b>																														
i. <u>Public Comment</u>	Telephonic and web comments were called for, and the phone lines were opened. No public comment was provided.																													
ii. Drug class review presentation by Prime.	Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.																													
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Khurana moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Board Member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Staci Dooley, APRN-C</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Staci Dooley, APRN-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																											
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Mark Crumby, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Leana Ramirez, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Staci Dooley, APRN-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											
iv. Presentation of recommendations for PDL inclusion by Prime.	Dr. Deoliveira recommended: <ul style="list-style-type: none"><li>• Remove doxylamine/pyridoxine 25-10mg OTC from the PDL, as this product has been discontinued</li><li>• Move Diclegis from non-preferred to preferred</li></ul>																													
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Gonzalez moved to approve the proposed changes as presented by Prime and Board Member Khurana seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p>																													

	<ul style="list-style-type: none"> <li>• Mark Decerbo, Pharm.D., Chair</li> <li>• Mark Crumby, Pharm.D</li> <li>• Elizabeth Gonzalez, Pharm.D.</li> <li>• Sapandeep Khurana, MD</li> <li>• Leana Ramirez, Pharm.D</li> <li>• Staci Dooley, APRN-C</li> </ul>	<div>Yes</div> <div>No</div> <div>Abst.</div> <div> <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> </div> <div> <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> </div> <div> <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> </div> <div> <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> </div> <div> <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> </div> <div> <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> </div>	
<b>E. For Possible Action: Discussion and possible adoption of Serotonin-receptor Antagonist/Combo.</b>			
i. <u>Public Comment</u>	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>		
ii. Drug class review presentation by Prime.	Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.		
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Khurana moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Board Member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p>	<div>Yes</div> <div>No</div> <div>Abst.</div> <div> <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> </div> <div> <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> </div> <div> <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> </div> <div> <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> </div>	

	<ul style="list-style-type: none"><li>• Leana Ramirez, Pharm.D <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li><li>• Staci Dooley, APRN-C <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/></li></ul>																													
iv. Presentation of recommendations for PDL inclusion by Prime.	<p>Dr. Deoliveira recommended:</p> <ul style="list-style-type: none"><li>• Remove Anzemet, Zofran, and Zuplenz from NPD list due to product discontinuation</li><li>• Remove Barhemsys from this PDL drug class; this drug was historically placed in this class; however, its mechanism of action differs from other agents in this class (as it is a dopamine antagonist indicated in post-op nausea and vomiting – whereas the other agents here work on serotonin); the removal of this drug from the PDL class would still make Barhemsys a covered agent however unmanaged by the PDL</li><li>• And then also define ondansetron ODT 16 mg strength as non-preferred, leaving all other strengths and dosage forms of ondansetron as preferred</li></ul>																													
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Gonzalez moved to approve the proposed changes as presented by Prime and Board Member Khurana seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Staci Dooley, APRN-C</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Staci Dooley, APRN-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																											
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Mark Crumby, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Leana Ramirez, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Staci Dooley, APRN-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											
F. For Possible Action: Discussion and possible adoption of Anticholinergics and Combination Products.																														

i. <u>Public Comment</u>	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>Public comment was provided by Christine Dube with AstraZeneca for Breztri Aerosphere.</p>																													
ii. Drug class review presentation by Prime.	<p>Dr. Deoliveira reviewed Tudorza Pressair clinical information.</p> <p>Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.</p>																													
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Gonzalez moved to accept the class as clinically and therapeutically equivalent presented by Prime and Board Member Khurana seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Staci Dooley, APRN-C</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Staci Dooley, APRN-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																											
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Mark Crumby, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Leana Ramirez, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Staci Dooley, APRN-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											
iv. Presentation of recommendations for PDL inclusion by Prime.	<p>Dr. Deoliveira recommended:</p> <ul style="list-style-type: none"><li>• Place umeclidinium/vilanterol (generic for Anoro Ellipta) as NPD</li><li>• Place tiotropium inhalation (generic for Spiriva) as NPD</li><li>• Move Tudorza Pressair from preferred to non-preferred</li><li>• And remove Lonhala Magnair from the PDL, as this product has been discontinued</li></ul>																													

v.	Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Leanna Ramirez moved to approve the proposed changes as presented by Prime and Board Member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Staci Dooley, APRN-C</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Staci Dooley, APRN-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																												
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																												
• Mark Crumby, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																												
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																												
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																												
• Leana Ramirez, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																												
• Staci Dooley, APRN-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																												
G.	For Possible Action: Discussion and possible adoption of <b>Anti-Hypoglycemic Agents.</b>																														
i.	<u>Public Comment</u>	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>																													
ii.	Drug class review presentation by Prime.	Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.																													
iii.	Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Gonzalez moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Board Member Khurana seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody></tbody></table>		Yes	No	Abst.																									
	Yes	No	Abst.																												

	<ul style="list-style-type: none"><li>• Mark Decerbo, Pharm.D., Chair</li><li>• Mark Crumby, Pharm.D</li><li>• Elizabeth Gonzalez, Pharm.D.</li><li>• Sapandeep Khurana, MD</li><li>• Leana Ramirez, Pharm.D</li><li>• Staci Dooley, APRN-C</li></ul>	<div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div> <div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div> <div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div> <div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div> <div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div> <div><div><input type="checkbox"/></div><div><input type="checkbox"/></div><div><input checked="" type="checkbox"/></div></div>	
iv. Presentation of recommendations for PDL inclusion by Prime.	<p>Dr. Deoliveira recommended:</p> <ul style="list-style-type: none"><li>• Remove GlucaGen Hypokit from the PDL, as this product has been discontinued</li><li>• However, to ensure appropriate access we would like to move the glucagon emergency kit (the generic for GlucaGen Hypokit, manufactured by Eli Lilly and Lupin) to preferred, keeping all other manufacturers of this product as non-preferred</li><li>• We also recommend to move Gvoke vial and syringe from non-preferred to preferred; and move Gvoke Pen from preferred to non-preferred</li></ul>		
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Gonzalez moved to approve the proposed changes as presented by Prime and Board Member Khurana seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <div><div><div><div></div><div>Yes</div></div><div><div></div><div>No</div></div><div><div></div><div>Abst.</div></div></div><div><div><div><div></div><div>• Mark Decerbo, Pharm.D., Chair</div></div><div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div></div><div><div><div><div></div><div>• Mark Crumby, Pharm.D</div></div><div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div></div><div><div><div><div></div><div>• Elizabeth Gonzalez, Pharm.D.</div></div><div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div></div><div><div><div><div></div><div>• Sapandeep Khurana, MD</div></div><div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div></div><div><div><div><div></div><div>• Leana Ramirez, Pharm.D</div></div><div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div></div><div><div><div><div></div><div>• Staci Dooley, APRN-C</div></div><div><div><input type="checkbox"/></div><div><input type="checkbox"/></div><div><input checked="" type="checkbox"/></div></div></div></div></div></div></div></div></div></div>		



H. For Possible Action: Discussion and possible adoption of ADHD Agents.																														
i. <u>Public Comment</u>	Telephonic and web comments were called for, and the phone lines were opened.  Public comment was provided by Patrick Carby with Supernus Pharmaceuticals for Qelbree.																													
ii. Drug class review presentation by Prime	Dr. Deoliveira reviewed Onyda XR clinical information.  Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.																													
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	Board Member Khurana moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Board Member Gonzalez seconded the motion.  A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable): <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Staci Dooley, APRN-C</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Staci Dooley, APRN-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																											
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Mark Crumby, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Leana Ramirez, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Staci Dooley, APRN-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											
iv. Presentation of recommendations for PDL inclusion by Prime.	Dr. Deoliveira recommended: <ul style="list-style-type: none"><li>• Removing Desoxyn brand from the PDL due to no longer participating in the Medicaid Drug Rebate Program (MDRP)</li><li>• Remove Ritalin LA from Preferred Drug List due to product</li></ul>																													

	<div>discontinuation</div> <ul style="list-style-type: none"><li>Remove Adhansia XR, Evekeo ODT, and Strattera from NPD list due to product discontinuation</li><li>Keep methylphenidate ER (the generic for Concerta) as preferred; and move the brand Concerta from preferred to non-preferred</li><li>Keep amphetamine salt combination ER (the generic for Adderall XR) as preferred; and move the Adderall XR brand from preferred to non-preferred</li><li>Move lisdexamfetamine capsule (generic for Vyvanse) from non-preferred to preferred; keeping the brand Vyvanse capsule preferred as well (co-prefer)</li><li>Move lisdexamfetamine chew tab (generic for Vyvanse) from non-preferred to preferred; and move the Vyvanse branded chewable tablet from preferred to non-preferred</li><li>Keep Daytrana patch as preferred, and move the methylphenidate patch (generic for Daytrana) from non-preferred to preferred (co-prefer)</li><li>And lastly, place Onyda XR suspension (clonidine ER suspension) as non-preferred</li></ul>									
v. Board Member Comments	Dr. Khurana provided a comment.									
vi. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<div>Board Member Khurana moved to approve the proposed changes as presented by Prime with the exception of moving Concerta to non-preferred. He proposed keeping Concerta as preferred and Board Member Gonzalez seconded the motion.</div> <div>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</div> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td><ul style="list-style-type: none"><li>Mark Decerbo, Pharm.D., Chair</li></ul></td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	<ul style="list-style-type: none"><li>Mark Decerbo, Pharm.D., Chair</li></ul>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.							
<ul style="list-style-type: none"><li>Mark Decerbo, Pharm.D., Chair</li></ul>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>							

	<ul style="list-style-type: none"><li>• Mark Crumby, Pharm.D</li><li>• Elizabeth Gonzalez, Pharm.D.</li><li>• Sapandeep Khurana, MD</li><li>• Leana Ramirez, Pharm.D</li><li>• Staci Dooley, APRN-C</li></ul>	<div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div> <div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div> <div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div> <div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div> <div><div><input type="checkbox"/></div><div><input type="checkbox"/></div><div><input checked="" type="checkbox"/></div></div>	
I. For Possible Action: Discussion and possible adoption of <b>Antidepressants, Other.</b>			
i. <u>Public Comment</u>	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>Public comment was provided by Lynda Finch with the manufacturer for Zurzuvaе.</p> <p>Public comment was provided by Dr. Sam Zand, Psychiatrist that practices in Nevada for Spravato.</p>		
ii. Drug class review presentation by Prime	<p>Dr. Deoliveira reviewed Exxua and Raldesy clinical information.</p> <p>Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.</p>		
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Gonzalez moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Board Member Khurana seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <div><div><div></div><div>Yes</div><div>No</div><div>Abst.</div></div><div><div><ul style="list-style-type: none"><li>• Mark Decerbo, Pharm.D., Chair</li><li>• Mark Crumby, Pharm.D</li><li>• Elizabeth Gonzalez, Pharm.D.</li></ul></div><div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div><div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div><div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div></div></div>		

	<ul style="list-style-type: none"><li>• Sapandeep Khurana, MD</li><li>• Leana Ramirez, Pharm.D</li><li>• Staci Dooley, APRN-C</li></ul>	<div><input checked="" type="checkbox"/><input type="checkbox"/><input type="checkbox"/></div> <div><input checked="" type="checkbox"/><input type="checkbox"/><input type="checkbox"/></div> <div><input type="checkbox"/><input type="checkbox"/><input checked="" type="checkbox"/></div>																													
iv. Presentation of recommendations for PDL inclusion by Prime.	Dr. Deoliveira recommended: <ul style="list-style-type: none"><li>• Remove Aplenzin and Wellbutrin XL from the NPD list due to the manufacturer no longer participating in the MDRP</li><li>• Additionally, we recommend to place Raldesy solution (new trazodone solution to market) as non-preferred</li><li>• And also place Exxua tab ER and Exxua tab ER titration pack as non-preferred</li></ul>																														
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Board Member Khurana moved to approve the proposed changes as presented by Prime and Board Member Gonzalez seconded the motion.  A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):  <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Staci Dooley, APRN-C</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Staci Dooley, APRN-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>		
	Yes	No	Abst.																												
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																												
• Mark Crumby, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																												
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																												
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																												
• Leana Ramirez, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																												
• Staci Dooley, APRN-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																												
J. For Possible Action: Discussion and possible adoption of <b>Dipeptidyl Peptidase-4 Inhibitors and Combinations with Metformin.</b>																															
i. Public Comment	Telephonic and web comments were called for, and the phone lines																														

		were opened.																													
		No public comment was provided.																													
ii.	Drug class review presentation by Prime	Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.																													
iii.	Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Gonzalez moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Chairperson Decerbo seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Staci Dooley, APRN-C</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Staci Dooley, APRN-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																												
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																												
• Mark Crumby, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																												
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																												
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																												
• Leana Ramirez, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																												
• Staci Dooley, APRN-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																												
iv.	Presentation of recommendations for PDL inclusion by Prime.	<p>Dr. Deoliveira recommended:</p> <ul style="list-style-type: none"><li>• Placing sitagliptin generic product as preferred, place Zituvio (branded sitagliptin product) as non-preferred, and move Januvia (another branded sitagliptin product) from preferred to non-preferred.</li><li>• Placing Brynovin (a branded sitagliptin solution formulation) as non-preferred.</li><li>• Placing Zituvimet and Zituvimet XR as preferred, placing sitagliptin/metformin (generic for Zituvimet) and sitagliptin/metformin ER (generic for Zituvimet XR) as non-preferred, and moving Janumet and Janumet XR from preferred to non-preferred.</li></ul>																													

<div>v.</div> <div>Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.</div>	<div>Chairperson Decerbo moved to approve the proposed changes as presented by Prime and Board Member Gonzalez seconded the motion.</div> <div>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</div> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Staci Dooley, APRN-C</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Staci Dooley, APRN-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																											
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Mark Crumby, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Leana Ramirez, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Staci Dooley, APRN-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											
<div>K.</div> <div>For Possible Action: Discussion and possible adoption of <b>Opiate Antagonists.</b></div>																														
<div>i.</div> <div><u>Public Comment</u></div>	<div>Telephonic and web comments were called for, and the phone lines were opened.</div> <div>No public comment was provided.</div>																													
<div>ii.</div> <div>Drug class review presentation by Prime.</div>	<div>Dr. Deoliveira reviewed Zurnai, Opvee, and Rextovy clinical information.</div> <div>Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.</div>																													
<div>iii.</div> <div>Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.</div>	<div>Board Member Gonzalez moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Board Member Khurana seconded the motion.</div> <div>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</div> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody></tbody></table>		Yes	No	Abst.																									
	Yes	No	Abst.																											

	<ul style="list-style-type: none"><li>• Mark Decerbo, Pharm.D., Chair</li><li>• Mark Crumby, Pharm.D</li><li>• Elizabeth Gonzalez, Pharm.D.</li><li>• Sapandeep Khurana, MD</li><li>• Leana Ramirez, Pharm.D</li><li>• Staci Dooley, APRN-C</li></ul>	<div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div> <div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div> <div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div> <div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div> <div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div> <div><div><input type="checkbox"/></div><div><input type="checkbox"/></div><div><input checked="" type="checkbox"/></div></div>	
iv. Presentation of recommendations for PDL inclusion by Prime.	<p>Dr. Deoliveira recommended:</p> <ul style="list-style-type: none"><li>• Remove Zimhi from the PDL, as this product has been discontinued.</li><li>• And place Zurnai (nalmafene autoinjector), Opvee (nalmefene nasal spray), and Rextovy (naloxone branded nasal spray) all as non-preferred products.</li></ul>		
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Gonzalez moved to approve the proposed changes as presented by Prime and Board Member Ramirez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div></div></div></div></div></div></div>		
L. For Possible Action: Discussion and possible adoption of <b>Multiple Sclerosis Agents: Injectable.</b>			
i. <u>Public Comment</u>	Telephonic and web comments were called for, and the phone lines were opened.		

	Public comment was provided by Lynda Finch for Tysabri.																													
ii. Drug class review presentation by Prime	Dr. Deoliveira reviewed Tyruko and Ocrevus Zunovo clinical information.  Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.																													
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	Board member Gonzalez moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Chairperson Decerbo seconded the motion.  A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):  <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Staci Dooley, APRN-C</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Staci Dooley, APRN-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																											
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Mark Crumby, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Leana Ramirez, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Staci Dooley, APRN-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											
iv. Presentation of recommendations for PDL inclusion by Prime.	Dr. Deoliveira recommends: • Keep Copaxone 20 mg/mL as preferred, while non-prefering the 40 mg/mL strength. • Moving glatiramer (the generic for Copaxone) 40 mg/mL to preferred, while keeping the 20 mg/mL strength non-preferred. • Placing Tyruko, the biosimilar for Tysabri, as non-preferred. • Placing Ocrevus Zunovo as non-preferred. • Removing Extavia from the NPD List due to product discontinuation.																													
v. Discussion by Board and action by Board for	Board Member Gonzlez moved to approve the proposed changes as presented by Prime and Board Member Khurana seconded the motion.																													



approval of drugs for inclusion on the PDL.	<p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Staci Dooley, APRN-C</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Staci Dooley, APRN-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																											
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Mark Crumby, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Leana Ramirez, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Staci Dooley, APRN-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											
<b>M.</b> For Possible Action: Discussion and possible adoption of a new class: <b>Neurokinin 1 (NK1) Receptor Antagonists.</b>																														
i. Public Comment	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>																													
ii. Drug class review presentation by Prime	<p>Dr. Deoliveira did a class review of the Neurokinin-1 Receptor Antagonists, to include fosaprepitant and aprepitant and their various formulations.</p> <p>Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.</p>																													
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Gonzalez moved to accept the class as clinically and therapeutically equivalent as presented by Prime and Board Member Mark Crumby seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p>																													

		<div> <div>Yes</div> <div>No</div> <div>Abst.</div> </div> <ul style="list-style-type: none"> <li>• Mark Decerbo, Pharm.D., Chair <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Mark Crumby, Pharm.D <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Elizabeth Gonzalez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Sapandeep Khurana, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Leana Ramirez, Pharm.D <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Staci Dooley, APRN-C <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/></li> </ul>	
iv.	Presentation of recommendations for PDL inclusion by Prime.	<p>Dr. Deoliveira recommends:</p> <ul style="list-style-type: none"> <li>• Placing aprepitant capsule and fosaprepitant as preferred products and non-preferring Aponvie, aprepitant pack, Cinvanti, Emend, and Focinvez.</li> </ul>	
v.	Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Chairperson Decerbo moved to approve the proposed changes as presented by Prime giving the latitude if Prime decides they want to make this class NK1 receptor antagonists and combos and kind of follow the same parallelism with the 5-HT3a and just put Akynzeo on the non-preferred side and Board Member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <div> <div>Yes</div> <div>No</div> <div>Abst.</div> </div> <ul style="list-style-type: none"> <li>• Mark Decerbo, Pharm.D., Chair <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Mark Crumby, Pharm.D <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Elizabeth Gonzalez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Sapandeep Khurana, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Leana Ramirez, Pharm.D <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Staci Dooley, APRN-C <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/></li> </ul>	
<b>N.</b>	<b>Annual Review: Established Drug Classes without Proposed Changes.</b>	<ul style="list-style-type: none"> <li>• <b>Analgesics:</b> Miscellaneous Analgesics, Neuropathic Pain/Fibromyalgia Agents, Mixed Acting Opioid Analgesics; Opiate Agonists; Opiate Agonists – Abuse Deterrents; Non-Opioid Analgesics; Non-Steroidal</li> </ul>	

	<p>Anti-Inflammatory Drugs (NSAIDs) – Oral</p> <ul style="list-style-type: none"> <li>• <b>Antihistamines:</b> H1 Blockers – Non-Sedating</li> <li>• <b>Anti-Infective Agents:</b> Aminoglycosides, Inhaled Aminoglycosides; Antivirals, Alpha Interferons, Anti-hepatitis Agents – Polymerase Inhibitors/Combination Products, Anti-hepatitis Agents – Ribavirin, Anti-herpetic Agents, COVID-19, Influenza Agents; Cephalosporins, Second-Generation Cephalosporins, Third-Generation Cephalosporins; Macrolides; Quinolones, Quinolones – 2<sup>nd</sup> generation, Quinolones – 3<sup>rd</sup> Generation; Topical Anti-Infectives, Vaginal</li> <li>• <b>Autonomic Agents:</b> Sympathomimetics, Self-Administered Epinephrine</li> <li>• <b>Biologic Response Modifiers:</b> Immunomodulators, Immunomodulators: Atopic Dermatitis, Targeted Immunomodulator, Colony Stimulating Factors, Immune Globulins; Multiple Sclerosis Agents, Oral, Specific Symptomatic Treatment</li> <li>• <b>Cardiovascular Agents:</b> Antihypertensive Agents, Angiotensin II Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors), Beta-Blockers, Calcium-Channel Blockers, Vasodilators – Inhaled, Vasodilators - Oral; Antilipemics, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibrin Acid Derivatives, HMG-CoA Reductase Inhibitors (Statins), Niacin Agents, Omega-3 Fatty Acids, PCSK9 Inhibitors</li> <li>• <b>Dermatological Agents:</b> Antipsoriatic Agents; Topical Analgesics; Topical Anti-infectives, Acne Agents: Topical, Benzoyl Peroxide, Antibiotics, and Combination Products, Impetigo Agents: Topical, Topical Antivirals, Topical Scabicides; Topical Antineoplastics, Topical Retinoids; Topical Steroids, Steroids Topical Low, Steroids Topical Medium, Steroids Topical High, Steroids Topical Very High</li> <li>• <b>Electrolytes and Renal Agents:</b> Phosphate Binding Agents; Potassium-Removing Agents</li> <li>• <b>Gastrointestinal Agents:</b> Antiulcer Agents, H2 Blockers, Proton Pump Inhibitors (PPIs); Functional Gastrointestinal Disorder Drugs: Constipation-Related; Functional Gastrointestinal Disorder Drugs: Diarrhea-Predominant; Gastrointestinal Anti-inflammatory Agents;</li> </ul>	
--	---	--

	<p>Gastrointestinal Enzymes</p> <ul style="list-style-type: none"> <li>• <b>Genitourinary Agents:</b> Benign Prostatic Hyperplasia (BPH) Agents, 5-Alpha Reductase Inhibitors, Alpha-Blockers; Bladder Antispasmodics</li> <li>• <b>Hematological Agents:</b> Anticoagulants, Injectable; Erythropoiesis-Stimulating Agents, Platelet Inhibitors</li> <li>• <b>Hormones and Hormone Modifiers:</b> Antidiabetic Agents, Alpha-Glucosidase Inhibitors/Amylin Analogs/Miscellaneous, Biguanides, Incretin Mimetics and Combinations, Meglitinides, Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors and Combinations, Sulfonylureas, Thiazolidinediones and Combinations; Insulins, Rapid Acting Insulins, Short-Intermediate Acting Insulins, Long-Acting Insulins, Pre-Mixed Insulin Combinations; Pituitary Hormones, Growth Hormone Modifiers; Progestins for Cachexia; Uterine Disorder Treatment</li> <li>• <b>Monoclonal Antibodies for the Treatment of Respiratory Conditions</b></li> <li>• <b>Musculoskeletal Agents:</b> Antigout Agents; Bone Resorption Inhibitors, Bisphosphonates, Nasal Calcitonins; Restless Leg Syndrome Agents; Skeletal Muscle Relaxants</li> <li>• <b>Neurological Agents:</b> Alzheimer's Agents, Cholinesterase Inhibitors, NMDA Receptor Antagonist; Anticonvulsants, Barbiturates; Anticonvulsants, Benzodiazepines, Hydantoins; Anti-Migraine Agents, Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists, Serotonin-Receptor Agonists (Triptans); Antiparkinsonian Agents, Dopamine Precursors, Non-Ergot Dopamine Agonists; Movement Disorders</li> <li>• <b>Ophthalmic Agents:</b> Antiglaucoma Agents; Ophthalmic Antihistamines; Ophthalmic Anti-infectives, Ophthalmic Macrolides, Ophthalmic Quinolones; Ophthalmic Anti-infective/Anti-inflammatory Combinations; Ophthalmic Anti-inflammatory agents, Ophthalmic Corticosteroids, Ophthalmic Nonsteroidal Anti-inflammatory Drugs (NSAIDs); Ophthalmics for Dry Eye Disease</li> <li>• <b>Otic Agents:</b> Otic Anti-infectives, Otic Quinolones</li> <li>• <b>Psychotropic Agents:</b> Antidepressants, Selective Serotonin Reuptake Inhibitors (SSRIs); Antipsychotics, Atypical Antipsychotics - Oral/Topical, Atypical Antipsychotics – Long Acting Injectable;</li> </ul>	
--	--	--

	<p>Anxiolytics, Sedatives and Hypnotics; Psychostimulants, Narcolepsy Agents</p> <ul style="list-style-type: none"> <li>• <b>Respiratory Agents:</b> Nasal Antihistamines; Respiratory Anti-Inflammatory Agents, Leukotriene Receptor Antagonists; Nasal Corticosteroids; Phosphodiesterase Type 4 Inhibitors or Combination; Long-Acting Maintenance Therapy, Inhaled Glucocorticoids, Glucocorticoids/Long-Acting Beta-2 Adrenergic (LABA) Combination Products, Long-Acting Beta Adrenergics (LABAs), Short-Acting Beta Adrenergics (SABAs), Ipratropium and Combinations</li> <li>• <b>Toxicology Agents:</b> Antidotes; Substance Abuse Agents</li> <li>• <b>Appendix A:</b> Sickle Cell Disease; HIV Prevention; Prenatal and Pediatric Vitamins</li> </ul>	
i. Public Comment	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>Public comment was provided by Brock Bizzell Senior Health Economics and Outcomes Research Liaison with United Therapeutics for Tyvaso DPI.</p> <p>Public comment was provided by Uche Ndefo Senior Medical Outcomes Liaison with UCB for Bimzelx.</p> <p>Public comment was provided by Kaysen Bala National Director of Health Economics and Outcomes Research with Ascendis Pharma for Skytrofa.</p> <p>Public comment was provided by Jalal Nait Hammoud for Siklos.</p> <p>Public comment was provided by Jenn Turner medical Science Liaison with Liquidia Corporation for Yutrepia.</p> <p>Public comment was provided by Greg Watts Medical Liaison with ARS Pharmaceuticals for Neffy.</p>	

	Public comment was provided by Taylor Chapman MSL from Louie Pharma for Erzofri.																													
ii. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Khurana moved to approve the PDL items without changes as presented by Prime and Board Member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Mark Decerbo, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Crumby, Pharm.D</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Elizabeth Gonzalez, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Sapandeep Khurana, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Leana Ramirez, Pharm.D</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Staci Dooley, APRN-C</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Leana Ramirez, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Staci Dooley, APRN-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																											
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Mark Crumby, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Leana Ramirez, Pharm.D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Staci Dooley, APRN-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											
O. Prime Reports	<p>New Drugs to Market and New Line Extensions</p> <ul style="list-style-type: none"><li>• New respiratory drug: depemokimab</li><li>• New cardiovascular drug: lerodalcibep</li><li>• New cardiovascular drug: plozasiran</li></ul>																													
4. Closing Discussion																														
A. Public comments on any subject	No public comments were provided.																													
B. Date and location of the next meeting.	Date: March 19, 2026 Location: Courtyard by Marriott Las Vegas Convention Center 3275 Paradise Road, Las Vegas, NV, 89109																													
C. Adjournment	Chairperson Decerbo adjourned the meeting at 3:51 PM.																													

#### **Attachment A – Members of the Public in Attendance**

Alisa Cadenhead	Heather Hornecker	Lisa Sherych
Allen Anna	Herbert Starr	Lisa Caraway
Angel Beus	Hugel David Williams	Lynda Finch
Ashlee Eltayeb	Jalal Nait Hammoud	Manzo Michelle
Ashley Jones	Jeana Colabianchi	Marc Parker
Brock Bizzell	Jenn Turner	Matthew Christopher Sheffield
Bruno Bevilacqua	Jenna Doerr	Ndefo Uche
Cade Grogan	Jennifer Golwyn	Patrick Harvey
Carmen Hinton	Jill Carroll	Peter Barrio
Casey Eastman	Jimmy Tran	Sabrina Schnur
Chris Dube	Joy Thomas	Shaneka L. Wiley
Chris Gilbert	Justin Clark	Shannon M. Groppenbacher
Christine Dube	Justin May	Shawn Akey
Connie Zheng	Kaysen Bala	Shelly Nickerson
Craig Sexton	Kenneth Garcia	Stephanie Abraham
Deborah Griffis	Kresh Rogina	Tayler Chapman
Dr.Sam Zand	Kyle Putnam	Zoe Houghton
Fushimi Brent	Lea Cartwright	

#### **Attachment B – Submitted Written Comment**

[Peaceful Mind Psychiatric Services - Qelbree](#)